CD8A and neoplasm: Adoptive T-cell therapy, involving ex vivo expansion and infusion of T cells containing tumor-specific CD8+ T cells, such as chimeric antigen receptor T (CAR-T) cells and tumor-infiltrating lymphocytes (TIL), has become a potent treatment modality for advanced hematological and solid malignancies refractory to conventional therapy (2, 3).